Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fresenius Kabi Ipsum is the specialized Active Pharmaceutical Ingredient (API) manufacturing division of Fresenius Kabi, headquartered in Italy. The company focuses on the development and large-scale production of high-quality APIs for both internal use within the Fresenius Kabi group and for external pharmaceutical customers globally. Their portfolio includes a wide range of therapeutic categories such as anesthetics, analgesics, and anti-infectives, produced under strict GMP standards. With manufacturing facilities in Villadose and Lodi, Fresenius Kabi Ipsum provides comprehensive services from chemical synthesis to regulatory support. The entity plays a crucial role in the global supply chain for critical care and hospital-based medications. It was originally founded as Ipsum S.p.A. before being integrated into the Fresenius Kabi network to bolster their vertical integration strategy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fresenius Kabi Ipsum.